本文選題：補(bǔ)腎活血方　切入點(diǎn)：腎虛血瘀型　出處：《湖北中醫(yī)藥大學(xué)》2014年碩士論文

【摘要】：目的: 通過觀察補(bǔ)腎活血方周期療法聯(lián)合來曲唑及克羅米芬治療腎虛血瘀型排卵障礙性不孕的臨床療效，客觀評(píng)價(jià)補(bǔ)腎活血方周期療法在促進(jìn)卵泡生長(zhǎng)、提高排卵率，改善臨床癥狀、促進(jìn)子宮內(nèi)膜生長(zhǎng)、提高妊娠率方面的作用。為臨床治療該病提供可靠的客觀依據(jù)。 方法: 將診斷為腎虛血瘀型排卵障礙性不孕癥的60例患者，隨機(jī)分為A組(治療組)、B組（對(duì)照組），每組各30例。對(duì)照組予以來曲唑（LE）、克羅米芬（CC）口服，，人絨毛膜促性腺激素(HCG)肌注治療；治療組在對(duì)照組治療方法的基礎(chǔ)上,加用補(bǔ)腎活血方周期療法，3個(gè)月經(jīng)周期為1療程，均治療2個(gè)療程。觀察治療前后兩組的臨床癥狀、卵泡發(fā)育、排卵率、妊娠率、子宮內(nèi)膜厚度、中醫(yī)癥候積分等方面的變化,進(jìn)行統(tǒng)計(jì)學(xué)分析，對(duì)兩組方法的臨床療效進(jìn)行評(píng)價(jià)。 結(jié)果: 1、兩組治療后卵泡大小、排卵率比較，治療組明顯優(yōu)于對(duì)照組（P＜0.05）；2、兩組促排卵綜合療效對(duì)比,顯愈率差異有顯著性(P＜0.05)；3、中醫(yī)證候積分比較，有顯著性差異（P＜0.05）；4、兩組子宮內(nèi)膜的厚度比較,治療組明顯優(yōu)于對(duì)照組（P＜0.05）；5、兩組妊娠率比較，有顯著性差異（P＜0.05）。 結(jié)論: 1、補(bǔ)腎活血方周期療法能提高卵巢對(duì)垂體促性腺激素的反應(yīng)性，從而促進(jìn)卵泡發(fā)育,調(diào)節(jié)黃體功能。2、LE、CC、補(bǔ)腎調(diào)周法聯(lián)合使用可以促進(jìn)卵泡的生長(zhǎng)、誘發(fā)排卵、改善子宮內(nèi)膜厚度、提高患者的妊娠率并改善臨床癥狀，既發(fā)揮了西藥高效促排卵作用,同時(shí)也彌補(bǔ)了西藥相關(guān)的副作用。3、補(bǔ)腎活血方周期療法，重在補(bǔ)腎壯陽、活血通絡(luò)，使機(jī)體氣血通暢、陰陽平衡、臟腑功能協(xié)調(diào)，從而充分調(diào)動(dòng)腎-天癸-沖任-胞宮軸的生理功能，提高受孕率。
[Abstract]:Objective:. By observing the clinical efficacy of Bushen Huoxue prescription combined with letrozole and clomiphene in the treatment of ovulatory dysfunction of kidney deficiency and blood stasis type, the objective evaluation of Bushen Huoxue prescription cycle therapy was to promote follicular growth and increase ovulation rate. To improve the clinical symptoms, promote the growth of endometrium, improve the pregnancy rate, and provide a reliable objective basis for clinical treatment of the disease. Methods:. Sixty patients with ovulatory disorder of kidney deficiency and blood stasis type were randomly divided into two groups: group A (control group, 30 cases, each group, 30 cases), control group, oral administration of letrozolide and clomiphene (CCL). The treatment group was treated by intramuscular injection of human chorionic gonadotropin (HCG), the treatment group was treated with Bushen Huoxue prescription on the basis of the treatment method of control group, 3 menstrual cycles were one course of treatment, all of them were treated for 2 courses. The clinical symptoms of the two groups were observed before and after the treatment. The changes of follicular development, ovulation rate, pregnancy rate, endometrial thickness, TCM symptom score and so on were analyzed statistically to evaluate the clinical efficacy of the two groups. Results:. 1. After treatment, the follicle size and ovulation rate in the treatment group were significantly better than those in the control group (P < 0.05). The comprehensive efficacy of the two groups in promoting ovulation was compared with that in the control group (P < 0.05). There was a significant difference in the apparent recovery rate between the two groups (P < 0.05), and the score of TCM syndromes was higher than that in the control group (P < 0.05). There was significant difference in endometrial thickness between the two groups (P < 0.05). The treatment group was better than the control group (P < 0.05). The pregnancy rate of the two groups was significantly higher than that of the control group (P < 0.05). Conclusion:. 1. The periodic therapy of tonifying kidney and activating blood circulation prescription can improve the response of ovary to pituitary gonadotropin, thus promote follicle development, regulate luteal function. The combination of tonifying kidney and regulating week method can promote follicle growth, induce ovulation, and improve endometrial thickness. Increasing the pregnancy rate and improving the clinical symptoms not only play a role in promoting ovulation effectively by western medicine, but also make up for the side-effect of western medicine. The cycle therapy of tonifying kidney and activating blood circulation is focused on invigorating kidney and strengthening yang, activating blood circulation, making body qi and blood unobstructed. The balance of yin and yang and the coordination of viscera function can fully mobilize the physiological function of kidney-Tiangui-Chong Ren-uterus axis and improve the pregnancy rate.
【學(xué)位授予單位】：湖北中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R711.6

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張嘉男,張蕓榕,王秀寶,楊錦清;補(bǔ)腎養(yǎng)血方對(duì)克羅米芬促排卵周期的影響[J];福建中醫(yī)藥;2005年05期

2 凌春波;補(bǔ)腎活血方配克羅米芬治療排卵障礙性不孕癥32例[J];廣西中醫(yī)藥;2005年02期

3 鄭敏,王亞平;當(dāng)歸多糖對(duì)人髓系多向造血祖細(xì)胞增殖分化的影響及其機(jī)理研究[J];解剖學(xué)雜志;2002年02期

4 姚石安;中醫(yī)治療卵巢功能失調(diào)的思路與方法[J];江蘇中醫(yī);1992年02期

5 占伏良;譚布珍;肖仲清;;來曲唑與克羅米芬對(duì)PCOS患者促排卵Meta分析[J];江西醫(yī)學(xué)院學(xué)報(bào);2009年12期

6 羅凌;蕭美茹;;補(bǔ)腎調(diào)沖方對(duì)排卵功能障礙性不孕癥患者卵泡發(fā)育及內(nèi)膜的影響[J];新中醫(yī);2008年04期

7 王慧穎,歐陽惠卿,李坤寅,于琳,黃寶玉;補(bǔ)腎活血中藥對(duì)無排卵功血患者子宮內(nèi)膜雌孕激素受體的影響[J];廣州中醫(yī)藥大學(xué)學(xué)報(bào);2004年01期

8 郭通航,劉雨生,駱麗華,周桂香,季靜娟;口服媽富隆并延長(zhǎng)氯米芬用藥時(shí)間治療耐氯米芬的無排卵患者[J];實(shí)用婦產(chǎn)科雜志;2005年05期

9 華啟天;朱笛霓;趙建礎(chǔ);;右歸丸治療腎陽虛不孕癥的實(shí)驗(yàn)研究[J];陜西中醫(yī);1990年01期

10 郭玉琪;張展;劉義;丁玉蓮;孫永玉;;克羅米酚對(duì)子宮內(nèi)膜發(fā)育的影響[J];生殖醫(yī)學(xué)雜志;2006年02期

本文編號(hào)：1662498